In the face of patent expirations on blockbuster drugs and declining innovation in the industry, pharma/biotech companies are restructuring their research and development operations and are pursuing an aggressive strategy of acquisitions, licensing deals and research collaborations in an attempt to fill the gaps in their product pipelines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1358/dnp.2009.22.1.1303817 | DOI Listing |
Publication Analysis
Top Keywords
overcoming obstacles
4
obstacles pharma/biotech
4
pharma/biotech industry
4
industry 2008
4
2008 update
4
update face
4
face patent
4
patent expirations
4
expirations blockbuster
4
blockbuster drugs
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!